Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study.

Mette JulsgaardDaniel C BaumgartSimon Mark Dahl JørgensenMette M HansenAnne GrosenBo M BibbyNiels UldbjergJens KjeldsenHeidi G SørensenLone Larsen Signe WildtPetra WeimersKent V HaderslevIda VindLise SvenningsenJørn BrynskovSøren LyhneThea VestergaardChristian L HvasJens Kelsennull null

Published in: Alimentary pharmacology & therapeutics (2021)

Neonatal vedolizumab clearance following intrauterine exposure is rapid. Infant vedolizumab levels did not correlate with the risk of infections during the first year of life. Continuation of vedolizumab throughout pregnancy is safe.

Keyphrases

ulcerative colitis
patients with inflammatory bowel disease
clinical trial
study protocol
preterm birth
low birth weight
pregnancy outcomes
quantum dots